Numerai GP LLC Buys New Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Numerai GP LLC acquired a new position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 8,612 shares of the medical research company's stock, valued at approximately $1,590,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Pinnacle Bancorp Inc. grew its holdings in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after purchasing an additional 65 shares during the period. Optiver Holding B.V. purchased a new stake in shares of Charles River Laboratories International during the fourth quarter valued at approximately $37,000. GeoWealth Management LLC grew its holdings in shares of Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after buying an additional 190 shares during the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Charles River Laboratories International during the fourth quarter valued at approximately $48,000. Finally, Tortoise Investment Management LLC grew its holdings in shares of Charles River Laboratories International by 77.7% during the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after buying an additional 115 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Performance

CRL traded up $2.11 during trading on Friday, hitting $141.00. The company's stock had a trading volume of 1,473,414 shares, compared to its average volume of 982,522. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15. The firm has a market cap of $6.93 billion, a PE ratio of 940.00, a P/E/G ratio of 4.54 and a beta of 1.50. The business's 50 day simple moving average is $135.43 and its 200-day simple moving average is $164.97.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. During the same period last year, the firm earned $2.27 earnings per share. The company's quarterly revenue was down 2.7% on a year-over-year basis. As a group, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on CRL shares. Mizuho cut their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. Evercore ISI upgraded shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price target on the stock in a report on Thursday, May 8th. JPMorgan Chase & Co. cut their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. UBS Group reiterated a "neutral" rating and set a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target on the stock in a report on Wednesday. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of "Hold" and a consensus target price of $172.31.

Insiders Place Their Bets

In other news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president now directly owns 19,513 shares of the company's stock, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO James C. Foster acquired 6,075 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The stock was purchased at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This represents a 3.42% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 5,040 shares of company stock worth $807,407. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).